Cancer screening - Principles, evaluation and implementation;Tumorscreening - Grundlagen, evaluation und implementation

Therapeutische Umschau

Volumn 70, Issue 4, 2013, Pages 195-203

  Egger, Matthias ^a   Zwahlen, Marcel ^a   Cerny, Thomas ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BREAST CANCER; CANCER SCREENING; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; MAMMOGRAPHY; PROSTATE CANCER;

EVIDENCE-BASED MEDICINE; HUMANS; MASS SCREENING; NEOPLASMS;

EID: 84875713650     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000390     Document Type: Article

References (25)

1. Raffle A, Gray MJA. Screening. Durchführung und Nutzen von Vorsorgeuntersuchungen. Bern: Verlag Hans Huber, Hogreve AG, 2009.
2. Egger M, Zwahlen M, Raffle A Screening. In: Egger M, Razum O (Hrsg.). Public Health. Sozial-und Präventivmedizin kompakt. Berlin: De Gruyter, 2012; 142-152.
3. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968.
4. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102: 605-613.
5. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ 2012; 344: e3502.
6. Zackrisson S, Andersson I, Janzon L et al. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ 2006; 332: 689-692.
7. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer 1977; 39: 2772-2782.
8. Andriole GL, Crawford ED, Grubb RL, 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
9. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1997; 16: 1017-29.
10. Hernan MA, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clinical Trials 2012; 9: 48-55.
11. Zwahlen M, Low N, Borisch B et al. Population based screening-the difficulty of how to do more good than harm and how to achieve it. Swiss Med Wkly 2010; 140: w13061.
12. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA: The Journal of the American Medical Association 1999; 281: 1900-1905.
13. Graham R, Mancher M, Miller Wolman D et al. Clinical Practice Guidelines We Can Trust. Washington, D.C.: Institute of Medicine, 2011; 1-266.
14. Brawley O, Byers T, Chen A et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA: the journal of the American Me dical Association 2011; 306: 2495-2499.
15. Egger M, Simon M, Schwappach D. Gesundheitssysteme. In: Egger M, Razum O (Hrsg.). Public Health. Sozial-und Präventivmedizin kompakt. Berlin: De Gruyter 2012, 95-118.
16. Perry N, Broeders M, de Wolf C et al. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth Edition. Luxembourg, 2006.
17. Perry N, Broeders M, de Wolf C et al. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition-summary document. Ann Oncol 2008; 19: 614-622.
18. Bouchardy C, Lutz JM, Kühni C. Krebs in der Schweiz. Stand und Entwicklung von 1983 bis 2007. Neuchâtel: NICER und Bundesamt für Statistik (BFS), 2011.
19. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostatecancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
20. Fontana RS, Sanderson DR, Woolner LB et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991; 67: 1155-1164.
21. Independent UK Panel on Breast Cancer Screening. The benefi ts and harms of breast cancer screening: an independent review. The Lancet; Published Online October 30, 2012, http://dx.doi.org/10.1016/ S0140-6736(12)61611-0.20.
22. Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991; 67: 1155-1164.
23. Bleyer A, Welch HG. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. New England Journal of Medicine 2012; 367: 1998-2005.
24. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95: 868-878.
25. Eden J, Levit L, Berg A, Morton S, Effectiveness CoSfSRoC Finding What Works in Health Care: Standards for Systematic Reviews. Washington, D.C.: Institute of Medicine, 2011, 1-318.